MammaPrint classifies patients as either high risk or low risk of recurrence over a 10-year period while BluePrint classifies patients by breast cancer subtype.
SensID specializes in the development, manufacture, and marketing or reference materials and quality controls for DNA-based diagnostics.
LabCorp will further invest in OmniSeq as part of the deal, which covers distribution of the latter's immune profiling and pan-cancer next-generation sequencing tests.
HalioDx said that Chinese oncologists will gain access to its Immunoscore assay for predicting the risk of recurrence of early-stage colon cancer.
Orto+ will be market and distribute Todos' TM-B2 test for breast cancer screening in Romania and Austria. The test is CE marked.
The test is designed to measure levels of seven auto-antibodies to tumor-associated antigens and can detect all forms of lung cancer at any stage.
Under the deal, Theradiag will have access to Immunodiagnostic's IDS-i10 automation system, and Immunodiagnostic will distribute Theradiag tests in 33 countries.
Addenbrooke' Hospital will manage and facilitate the fulfillment orders of the firm's PredictSure IBD orders, as well as receive and process all samples.
Under the agreement, Menarini will immediately begin distributing Curetis' PCR-based system in Germany, France, Benelux, the UK, and Switzerland.
The partners inked a licensing deal to market and distribute TGen's DeepChek-TB as a compact, portable, and affordable diagnostic model for physician use.